New hope for hepatitis c: triple therapy shows promise in late-stage trial
NCT ID NCT01753570
First seen Jan 08, 2026 · Last updated Jun 17, 2026 · Updated 29 times
Summary
This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main goal was to see if the virus became undetectable 24 weeks after treatment ended, indicating a sustained response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C(CHC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, 213-8587, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.